C
큐라티스
348080KOSDAQ52.0 / 100
Reference Date: 2026-10-23
Financial Score21.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Curatis develops vaccines using its platform technology, including QTP101 (tuberculosis prevention), QTP105 (schistosomiasis prevention), and QTP104 (next-generation mRNA-based COVID-19 vaccine). QTP101 has received global Phase 2b/3 trial approval, and the company also provides CMO/CDMO services and open innovation solutions for drug development.
Number of Employees
47people
Average Salary
58.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.93Industry Average 1.204.0Point
In line with industry avg
ROE
-91.68Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
0.06Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲246.8% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲15.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -92.3% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position6.0Point
52w upper range (64%)
Current 3,195Won52-week high 4,81552-week low 309
1-month return1.0Point
1m -13.77% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-10-08